Maseko, Thando Glory
Ngubane, Slindile
Letsoalo, Marothi
Rambaran, Santhuri
Archary, Derseree
Samsunder, Natasha
Perumal, Rubeshan
Chinappa, Surie
Padayatchi, Nesri
Naidoo, Kogieleum
Sivro, Aida
Funding for this research was provided by:
DST-NRF Centre of Excellence (CoE) in HIV Prevention (96354)
Poliomyelitis Research Foundation (21/58)
SAMRC Self-Initiated Grant and the NRF of South Africa Thuthuka (TTK160517165310)
NRF Research Career Advancement Fellowship (RCA13101656388)
Poliomyelitis Research Foundation of South Africa (17/02)
EDCTP Senior Fellowship (TMA2018SF-2467)
EDCTP Career Development Fellowship (TMA2016CDF-1582)
Article History
Received: 9 January 2023
Accepted: 19 August 2023
First Online: 31 August 2023
Declarations
:
: The CAPRISA 020 Individualized M(X)drug-resistant TB Treatment Strategy Study (InDEX) was approved by the University of KwaZulu-Natal (UKZN) Biomedical Research Ethics Committee (BREC, BFC584/16) and registered with the South African Clinical Trials Register (NCT03237182). This sub-study was approved by the University of KwaZulu-Natal Biomedical Research Ethics Committee (BREC/00002197/2020). All the experiments were performed in accordance with the Helsinki Declaration. All study participants provided written informed consent for the use of stored biological specimens.
: Not Applicable.
: The authors declare no conflict of interests.